Qrons Inc. is a biotechnology company. The Company is focused on developing biotech products, treatments and technologies to combat neuronal diseases. It seeks to engage in arrangements with companies and institutions that are developing technologies in the fields of artificial intelligence, machine learning, molecular biology, stem cells and tissue engineering, for deployment in neuronal diseases. The Company has developed two product candidates, QS100TM for treating penetrating brain injuries and QS200TM, for treating concussions and other diffused axonal injuries. Both QS100TM and QS200TM integrate, anti-brain inflammation synthetic hydrogel and modified mesenchymal stem cells (MSCs) and smart synthetic material. Its QS100TM is an injury-specific, three-dimensional (3D) printable, implantable MSCs-synthetic hydrogel to treat penetrating brain injuries and QS200TM is an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries referred to concussions.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)